Opus Genetics (IRD) EBIT Growth (3y) (2013 - 2026)

Opus Genetics (IRD) EBIT Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 16.96%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 38.78%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 13.47%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -12.10%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 69.02%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Opus Genetics 3.27 Mn -56.73 Mn - -32.82%

Historic Data

Download Data
DateValue
Mar 31, 2026 -32.82%
Dec 31, 2025 -32.66%
Sep 30, 2025 -22.35%
Jun 30, 2025 -21.72%
Mar 31, 2025 -15.12%
Dec 31, 2024 -83.55%
Sep 30, 2024 -23.69%
Jun 30, 2024 -5.28%
Mar 31, 2024 -14.12%
Dec 31, 2023 27.12%
Sep 30, 2023 74.11%
Jun 30, 2023 -62.24%
Mar 31, 2023 -30.88%
Dec 31, 2022 89.67%
Sep 30, 2022 -25.78%
Jun 30, 2022 -18.22%
Mar 31, 2022 -18.23%
Dec 31, 2021 -7.38%
Sep 30, 2021 3.33%
Jun 30, 2021 -12.58%